CClinicalTrials.gg
Not yet recruitingNCT06669260TEThAUpdated Nov 1, 2024

Evaluating QoL and Postoperative Complications Using TEThA Technique in the Treatment of Tributary Veins

An observational study in Varicose Veins, Quality of Life and Laser, sponsored by Nara Medeiros Cunha de Melo Vasconcelos. Not yet recruiting. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-11-01.

Sponsored by Nara Medeiros Cunha de Melo Vasconcelos · Observational

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 2 months ago, but the record still lists the study as not yet recruiting.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
20
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Endovenous laser thermoablation is a well-established alternative for the treatment of tributary veins. We believe that it is possible to improve the techniques described in the literature, aiming not only to allocate the laser fiber within the venous lumen, but mainly to transfix the vessel walls - a technique called TEThA (Transfixing Endovenous Thermal Ablation).

Read the detailed description

Endovenous laser thermoablation is an alternative for the treatment of tributary veins that is not yet one of the main alternatives in our specialty's consensus. In order to treat tributary veins applying laser, several punctures and the complete placement of introducer catheters are recommended in order to position the endolaser fiber in the lumen of the varicose vein before performing thermoablation of the saphenous veins. However, we believe that it is possible to perform an adequate treatment with a smaller number of punctures, aiming not only to place the laser fiber inside the venous lumen, but mainly to transfix the vessel walls - a technique called TEThA (Transfixing Endovenous Thermal Ablation). Our aim is to carry out a prospective cohort study to assess the Aberdeen score in patients undergoing the TEThA technique for the treatment of tributary veins.

02

Conditions studied

  • Varicose Veins
  • Quality of Life
  • Laser

Browse trials for

03

In context

Varicose Veins

253 studies on the registry are indexed under Varicose Veins; 35 are open to participants now.

This study's planned enrollment of 20 is below the median of 124 across 79 observational studies indexed under Varicose Veins.

Browse Varicose Veins studies →

Lead sponsor

This is the only study on the registry with Nara Medeiros Cunha de Melo Vasconcelos as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Participants with tributary veins bigger than 2mm, presenting saphenous truncal incompetency scoring from C2 to C6 in CEAP

Inclusion criteria

Patients with varicose veins > 2mm associated with reflux of great or small saphenous veins with CEAP C2 to C6

Exclusion criteria

Exclusion Criteria:

Patients under 18 years Acute or previous thrombophlebitis or deep vein thrombosis. Pregnant patient. Reject the Informed Consent Form.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • TEThA technique

    TEThA technique

    Procedure: TEThA technique

Interventions

  • ProcedureTEThA technique

    Patient in an orthostatic position, previously marked varicose veins will be punctured with a tracing adjacent to them, surrounding their edges. Applying an augmented reality device and Doppler ultrasound (Doppler USG), the marking will be complemented in the supine position. These punctures will in turn be carried out using the TEThA technique - endovenous thermoablation of tributary veins by means of transfixation - and will be done sequentially as they are treated one by one with endo- and perivenous thermoablation under generous tumescence with 0.08% lidocaine in saline solution. The laser used to treat the tributary veins will also be 1470 nm and will be fired as the fiber is removed at a speed of 1 mm/sec and power ranging from 5 to 7 watts.

06

What researchers measure

Primary outcomes

  1. Quality of Life score using Aberdeen Varicose Veins Questionnaire (AVVQ)

    AVVQ is an easy-to-administer, self-administered instrument, it consists of 3 dimensions, which are physical, sociofunctional and psychological. It is interpreted through a score, which can vary between 0 and 100, with 0 representing no evidence of varicose veins and 100 the most serious problem associated with varicose veins.

    Time frame: Baseline, Timepoints post-procedire: 1 month, 3 months, 6 months

  2. Quality of life score using the Chronic Venous Insufficiency Questionnaire (CIVIQ)

    CIVIQ-14 is a questionnaire based on three dimensions - pain, physical and psychological, based on a scale from 1 to 5 (no trouble, slight, moderate, considerable, severe). Based on inputs, Global Index Score (GIS) will be tabulated, ranging from 0 to 100 - the higher the value, the poorer the quality of life.

    Time frame: Timepoints post-procedire: 1 month, 3 months, 6 months

Secondary outcomes

  1. Hyperpigmentation

    Presence or absence of hyperpigmentation in the limb treated by a endovenous laser with TEThA tecnique (phototodocumentation, US Doppler)

    Time frame: Baseline, 30 days and 180 days

  2. Presence of induration

    Induration noticed on the saphenous vein path (phototodocumentation, US Doppler)

    Time frame: 30 days and 180 days

  3. Presence of Paresthesia

    Presence or absence of paresthesia in the limb treated by endovenous laser TEThA technique

    Time frame: 30 days and 180 days

  4. Skin burns

    Presence or absence of skin burns in the limb treated by a endovenous laser with TEThA technique

    Time frame: 7 days

  5. Lymphedema

    Presence or absence of lymphedema diagnosed by exam of lymphoscintigraphy in the limb treated by endovenous laser TEThA technique

    Time frame: 30 days and 180 days

  6. Sclerothrombus

    Presence of Sclerothrombus (US doppler)

    Time frame: 7 days

  7. Complementary treatment

    Percentage of participants with residual veins

    Time frame: 180 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Salim S, Machin M, Patterson BO, Onida S, Davies AH. Global Epidemiology of Chronic Venous Disease: A Systematic Review With Pooled Prevalence Analysis. Ann Surg. 2021 Dec 1;274(6):971-976. doi: 10.1097/SLA.0000000000004631. PubMed 33214466 ↗
  • Lurie F, Passman M, Meisner M, Dalsing M, Masuda E, Welch H, Bush RL, Blebea J, Carpentier PH, De Maeseneer M, Gasparis A, Labropoulos N, Marston WA, Rafetto J, Santiago F, Shortell C, Uhl JF, Urbanek T, van Rij A, Eklof B, Gloviczki P, Kistner R, Lawrence P, Moneta G, Padberg F, Perrin M, Wakefield T. The 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord. 2020 May;8(3):342-352. doi: 10.1016/j.jvsv.2019.12.075. Epub 2020 Feb 27. Erratum In: J Vasc Surg Venous Lymphat Disord. 2021 Jan;9(1):288. doi: 10.1016/j.jvsv.2020.11.002. PubMed 32113854 ↗
  • De Maeseneer MG, Kakkos SK, Aherne T, Baekgaard N, Black S, Blomgren L, Giannoukas A, Gohel M, de Graaf R, Hamel-Desnos C, Jawien A, Jaworucka-Kaczorowska A, Lattimer CR, Mosti G, Noppeney T, van Rijn MJ, Stansby G, Esvs Guidelines Committee, Kolh P, Bastos Goncalves F, Chakfe N, Coscas R, de Borst GJ, Dias NV, Hinchliffe RJ, Koncar IB, Lindholt JS, Trimarchi S, Tulamo R, Twine CP, Vermassen F, Wanhainen A, Document Reviewers, Bjorck M, Labropoulos N, Lurie F, Mansilha A, Nyamekye IK, Ramirez Ortega M, Ulloa JH, Urbanek T, van Rij AM, Vuylsteke ME. Editor's Choice - European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg. 2022 Feb;63(2):184-267. doi: 10.1016/j.ejvs.2021.12.024. Epub 2022 Jan 11. No abstract available. Erratum In: Eur J Vasc Endovasc Surg. 2022 Aug-Sep;64(2-3):284-285. doi: 10.1016/j.ejvs.2022.05.044. PubMed 35027279 ↗
  • Vasconcelos NMCM, Kumakura HS, Grill MH, Silva MCE. Treatment of the small saphenous vein and tributary veins with endolaser associated with ultrasound-guided foam in a patient with post-thrombotic syndrome: presenting the TEThA technique. J Vasc Bras. 2024 Nov 29;23:e20230142. doi: 10.1590/1677-5449.202301422. eCollection 2024. PubMed 39629276 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06669260
Lead sponsor
Nara Medeiros Cunha de Melo Vasconcelos
Collaborators
Gabriela de Oliveira Buril, Marcelo Halfen Grill
Responsible party
Nara Medeiros Cunha de Melo Vasconcelos (MD, Science Valley Research Institute) — Sponsor-investigator
First posted
Nov 1, 2024
Start date
Nov 21, 2024 (estimated)
Primary completion
Jul 22, 2025 (estimated)
Completion
Jul 22, 2025 (estimated)
Last update
Nov 1, 2024

Study contacts

Eduardo Ramacciotti, MD, PhD
Contact
eduardoramacciotti@gmail.com
+55 11 4040-8670

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion